One of the newest active mass tort MDLs in the federal court system officially opened its doors in February 2026, and patients who received the Cartiva Synthetic Cartilage Implant for big-toe arthritis are now at a critical decision point. The Cartiva implant lawsuit landscape shifted dramatically when the Judicial Panel on Multidistrict Litigation consolidated all federal cases into a single coordinated proceeding — just months after a sweeping FDA recall confirmed what many injured patients had long suspected: this device was failing at rates no one warned them about.
What Is the Cartiva Synthetic Cartilage Implant?
The Cartiva Synthetic Cartilage Implant (SCI) is a small cylindrical device made from polyvinyl alcohol (PVA) hydrogel — sometimes called a cryogel — designed to treat hallux rigidus, a progressive arthritic condition affecting the first metatarsophalangeal joint at the base of the big toe. Rather than fusing the joint and permanently eliminating motion, the Cartiva SCI was marketed as a motion-preserving alternative: a way to relieve pain while keeping the joint functional.
For patients suffering from debilitating big-toe arthritis, that promise was compelling. Fusion surgery, while effective, permanently eliminates joint movement and comes with its own recovery challenges. The Cartiva implant offered what seemed like a better path forward — until, for thousands of patients, it didn’t. Approximately 22,000 people were implanted with the device before the recall, and later reports suggest the failure rate may affect up to two-thirds of patients — a staggering figure that underlies the scale of potential harm at issue in this litigation. The FDA has estimated actual Cartiva success rates ranged from just 21% to 46%, substantially below the performance figures the manufacturer marketed to physicians and patients alike. To understand how defective medical device claims are evaluated and what compensation may be available, patients can explore a medical malpractice calculator as a starting point for understanding the scope of their potential damages.
The FDA Recall That Changed Everything
In October 2024, the U.S. Food and Drug Administration issued a Class II recall for the Cartiva Synthetic Cartilage Implant, covering all lots distributed from July 2016 through October 2024. A Class II recall designation means the FDA has determined that use of the device may cause temporary or medically reversible adverse health consequences, though the probability of serious harm is considered lower than a Class I recall.
The language in the FDA recall record is striking in its specificity. According to the recall documentation, the FDA stated that implanted patients may experience a higher-than-expected occurrence of revision, removal, implant subsidence, displacement, pain, nerve damage, or fragmentation. That language — “higher-than-expected” — sits at the heart of every pending Cartiva implant lawsuit: patients allege they were never warned those risks existed at the rates the manufacturer knew or should have known about. The scale of reported harm is significant: as of mid-2026, the FDA adverse event database contained 236 submissions involving Cartiva implants, including 102 revision operations. Analysis of those adverse event reports indicates that approximately 73.7% of patients reporting problems required surgical removal of the device, and 67.7% ultimately underwent toe fusion — the very outcome the Cartiva implant was supposed to help them avoid.
MDL 3172: Breaking Down the Federal Consolidation
In February 2026, the Judicial Panel on Multidistrict Litigation (JPML) formally established MDL 3172, consolidating all federally filed Cartiva implant lawsuits into a single coordinated proceeding in the Eastern District of Arkansas. MDL consolidation is the standard mechanism federal courts use when a large number of cases share common factual questions — in this instance, the design, manufacturing, testing, marketing, and post-market surveillance of the Cartiva Synthetic Cartilage Implant.
Consolidation does not mean plaintiffs lose their individual cases. Each lawsuit remains a separate action with its own plaintiff, injuries, and facts. What MDL consolidation accomplishes is efficiency: rather than having dozens or eventually hundreds of federal judges across the country independently managing duplicative discovery, expert witness battles, and pretrial motions, a single transferee judge oversees all pretrial proceedings. If the MDL does not resolve through settlement, individual cases can be remanded back to their home districts for trial.
Why the Eastern District of Arkansas?
The JPML selected the Eastern District of Arkansas as the transferee court for MDL 3172. While this may seem like an unusual venue for a nationally significant medical device case, the JPML’s selection criteria focus on practical factors: the location of key witnesses and documents, the caseload of the receiving court, and the experience of the assigned judge in managing complex litigation. The Eastern District of Arkansas has a track record with product liability and medical device MDLs, making it a logical choice for a proceeding of this scope and complexity.
The JPML Rejected Defendants’ Consolidation Objections
Defendants opposed consolidation, a standard defensive posture in MDL proceedings. Manufacturers and distributors typically prefer to litigate cases individually, where resources and asymmetries of information favor well-funded corporate defendants over individual plaintiffs. The JPML reviewed the arguments and rejected the defendants’ objections, finding that the common factual questions surrounding the Cartiva device — particularly those related to alleged design defects, failure to warn, and the FDA recall — warranted centralized management.
Who Are the Defendants in the Cartiva Implant Lawsuit?
The primary defendants named in Cartiva implant lawsuits are Stryker Corporation and its subsidiary Wright Medical Group. Wright Medical originally developed and commercialized the Cartiva SCI in the United States following the device’s 510(k) clearance by the FDA. Stryker, one of the largest medical device companies in the world, acquired Wright Medical in 2020, inheriting both the Cartiva product line and the legal exposure that has since materialized.
Plaintiffs allege that both entities bear responsibility — Wright Medical for the original design, clinical trial conduct, regulatory submissions, and marketing of the device, and Stryker for continuing to sell and promote the implant after acquisition while allegedly failing to adequately address mounting evidence of device failures. The corporate succession between Wright Medical and Stryker is a significant legal issue in the litigation, touching on questions of successor liability and the allocation of responsibility between the original manufacturer and the acquiring company.
Core Allegations and Patient Injuries
What Plaintiffs Are Alleging
The lawsuits consolidated in MDL 3172 assert a range of product liability and related claims. At their core, plaintiffs allege that the Cartiva Synthetic Cartilage Implant was defectively designed, that defendants knew or should have known about the device’s propensity to fail at rates far exceeding what was disclosed, and that patients and their physicians were not given adequate warnings to make informed decisions about implantation.
Specific legal theories typically include strict liability for design defect, strict liability for failure to warn, negligence, breach of express and implied warranty, and in some cases fraud and misrepresentation claims stemming from the marketing of the device. Plaintiffs point to the gap between the manufacturer’s marketed performance figures — which the FDA has found ranged from just 21% to 46% in actual success rates — and the optimistic clinical claims used to promote the device to surgeons and patients as central evidence of misrepresentation.
A recurring theme in the litigation is the allegation that defendants were aware of post-market signals indicating higher-than-expected failure rates long before the 2024 recall — and that they failed to act on that information or disclose it to the medical community and patients. Plaintiffs further allege that the 510(k) clearance pathway used to bring the Cartiva SCI to market, which relies on substantial equivalence to a predicate device rather than independent clinical proof of safety and efficacy, was insufficient given the novel nature of the hydrogel implant technology.
Injuries Reported by Claimants
The injuries at the center of Cartiva implant lawsuits range from significant pain and functional impairment to the need for additional surgeries. Common reported injuries include:
- Implant subsidence — the device sinking into the bone of the metatarsal head
- Implant displacement or migration from the surgical site
- Device fragmentation, with pieces of the PVA hydrogel breaking off within the joint
- Persistent or worsening joint pain following implantation
- Nerve damage in the toe or foot
- Revision surgery to address device failure
- Complete surgical removal of the implant
- Salvage fusion surgery — the very procedure the Cartiva implant was intended to replace
That last injury is particularly significant from a damages perspective. Analysis of FDA adverse event reports indicates that approximately 67.7% of patients who reported problems ultimately underwent toe fusion. Patients who received the Cartiva implant specifically to avoid fusion — and who ultimately required it anyway — have experienced not only the physical harm of multiple surgeries but the loss of the functional benefit they were explicitly promised.
Key Facts and Timeline: Cartiva MDL 3172 at a Glance
- Device: Cartiva Synthetic Cartilage Implant (SCI), a PVA hydrogel device for hallux rigidus treatment
- Original Manufacturer: Wright Medical Group
- Current Defendant: Stryker Corporation (acquired Wright Medical in 2020)
- FDA Clearance Pathway: 510(k), cleared on the basis of substantial equivalence
- Distribution Period Covered by Recall: July 2016 – October 2024
- FDA Recall Classification: Class II (October 2024)
- Estimated Patients Implanted: Approximately 22,000
- FDA Adverse Event Submissions: 236 as of mid-2026, including 102 revision operations
- FDA-Estimated Success Rate: 21% to 46% — substantially below marketed figures
- Surgical Removal Rate Among Adverse Event Reporters: Approximately 73.7%
- Toe Fusion Rate Among Adverse Event Reporters: Approximately 67.7%
- MDL Established: February 2026
- MDL Designation: MDL 3172
- Transferee Court: Eastern District of Arkansas
- Pending Cases as of October 1, 2026: 21
- Plaintiffs’ Leadership Appointed: October 5, 2026 (13 attorneys appointed to leadership roles)
- Next Key MDL Date: October 8, 2026 telephone status hearing
Where the Litigation Stands Now and What Comes Next
As of October 2026, MDL 3172 is in its early organizational phase — a stage that is typical for newly formed multidistrict proceedings and that tends to move more quickly than many plaintiffs expect once the court establishes its pretrial framework. On October 5, 2026, a federal judge appointed 13 plaintiffs’ attorneys to leadership roles responsible for coordinating discovery and managing the consolidated litigation on behalf of all plaintiffs. That leadership appointment is a significant structural milestone: it means the MDL now has an organized plaintiff-side team capable of efficiently conducting the large-scale discovery that complex medical device litigation demands.
With 21 pending cases as of October 1, 2026, and a telephone status hearing scheduled for October 8, 2026, the court is actively setting the procedural calendar that will govern the months ahead. In the near term, the litigation is likely to focus on the exchange of initial disclosures, the development of a case management order governing discovery timelines and expert witness schedules, and the potential selection of bellwether cases — representative individual lawsuits that the parties will prepare for trial in order to test legal theories and damages ranges that may inform eventual broader settlement discussions.
The number of pending cases is expected to grow as more patients learn about the recall, connect their ongoing symptoms to device failure, and consult with attorneys about their legal options. MDL proceedings of this type often see significant case growth during the early organizational phase, particularly as plaintiff leadership ramps up public outreach and case evaluation efforts.
From a litigation strategy standpoint, the coming months will be critical. Plaintiff leadership will be seeking internal documents from Stryker and Wright Medical relating to clinical trial data, post-market surveillance findings, communications about device failure rates, and marketing materials — all of which bear directly on the core allegations that defendants knew more than they disclosed. Defendants, meanwhile, will likely challenge the scope of discovery, contest causation theories, and explore early dispositive motion practice. The October 8 status hearing is an early opportunity for the court to signal how it intends to manage the pace and scope of these competing litigation priorities.
Frequently Asked Questions About the Cartiva Implant Lawsuit
Who qualifies to file a Cartiva implant lawsuit in 2026?
Patients who received a Cartiva Synthetic Cartilage Implant and subsequently experienced device failure, complications, or required revision or removal surgery may have grounds to file a lawsuit. The strongest potential claims involve patients who underwent revision surgery, device removal, or salvage fusion after implantation — particularly those who were not adequately warned about the risk of these outcomes. Because statutes of limitations vary by state and begin running at different triggering events (date of injury, date of diagnosis, or date the patient reasonably should have discovered the connection between the device and their harm), patients with concerns should consult with an attorney as soon as possible to preserve their legal rights.
What is MDL 3172 and how does it affect individual cases?
MDL 3172 is the federal multidistrict litigation proceeding consolidating all federally filed Cartiva implant lawsuits before a single judge in the Eastern District of Arkansas. Consolidation streamlines pretrial proceedings — particularly discovery — by avoiding duplicative effort across multiple courts. Importantly, individual plaintiffs retain their separate cases within the MDL framework. If the litigation does not resolve through settlement, cases can be returned to their original home districts for trial. MDL consolidation does not eliminate individual claims; it coordinates them for efficiency during the pretrial phase.
What are the main allegations against Stryker and Wright Medical in the Cartiva lawsuit?
Plaintiffs allege that the Cartiva Synthetic Cartilage Implant was defectively designed and that defendants failed to adequately warn patients and physicians about the device’s true failure rates. Central to these claims is the gap between marketed performance claims and actual outcomes: the FDA has estimated actual success rates of only 21% to 46%, far below what the manufacturer represented. Plaintiffs further allege that defendants had access to post-market data indicating higher-than-expected failure rates before the 2024 recall and failed to act on or disclose that information. Legal theories typically include strict product liability, negligence, failure to warn, breach of warranty, and in some cases fraud.
How long will the Cartiva MDL litigation take, and when might there be a settlement?
MDL proceedings of this type typically unfold over multiple years. The Eastern District of Arkansas will first need to oversee substantial discovery, manage expert witness proceedings, and likely conduct bellwether trials before the parties have sufficient information to seriously negotiate a global settlement. Based on comparable medical device MDLs, plaintiffs should expect the litigation to remain active well into 2027 and potentially beyond. Settlement timelines are inherently unpredictable and depend heavily on how courts rule on dispositive motions, how bellwether trials perform, and whether defendants determine that settlement is preferable to continued litigation risk. The appointment of plaintiff leadership in October 2026 is an early positive structural development, but meaningful settlement discussions are unlikely before discovery and early bellwether proceedings are substantially complete.
Does it matter which state you live in for a Cartiva implant lawsuit?
For cases filed in federal court and consolidated in MDL 3172, the transferee court in Arkansas manages all pretrial proceedings regardless of where a plaintiff lives or where their surgery occurred. However, the substantive law that applies to each case — including statutes of limitations, product liability standards, and damages caps — typically derives from the state where the plaintiff resides or where the injury occurred. This means that while the MDL provides a unified procedural home, the applicable legal standards can vary meaningfully from plaintiff to plaintiff. An attorney experienced in medical device litigation can evaluate how your state’s specific laws affect the strength and value of your potential claim.
Victoria Chambers is a mass tort and class action research analyst with extensive knowledge of multi-district litigation (MDL), defective product cases, dangerous drug lawsuits, and toxic exposure claims across the United States. Victoria is not an attorney and the information provided is for educational purposes only.